Question 1

Does Morgan Stanley own PTGX stock?

Accepted Answer

Yes. As of its Q2 2026 13F, Morgan Stanley holds 905,992 shares of PTGX (Protagonist Therapeutics), worth $111.1M.

Question 2

How many shares of PTGX does Morgan Stanley own?

Accepted Answer

As of its Q2 2026 13F, Morgan Stanley holds 905,992 shares of PTGX (Protagonist Therapeutics).

Question 3

What is Morgan Stanley's PTGX position worth?

Accepted Answer

As of its Q2 2026 13F, Morgan Stanley's PTGX position is worth $111.1M.

Question 4

Is Morgan Stanley buying or selling PTGX?

Accepted Answer

In Q2 2026, Morgan Stanley reduced its PTGX position by 112,230 shares (-11.0%).

Question 5

When did Morgan Stanley first buy PTGX?

Accepted Answer

Morgan Stanley already held PTGX in its Q2 2024 13F, the earliest on record, and has listed it in 9 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Decreased	905,992	-11.0%	$111.1M	0.0%	$122.58	0
2026-Q1	Increased	1M	+15.8%	$107.3M	0.0%	$105.40	35
2025-Q4	Increased	879,024	+14.4%	$76.8M	0.0%	$87.34	34
2025-Q3	Decreased	768,359	-11.6%	$51M	0.0%	$66.43	0
2025-Q2	Increased	868,963	+74.8%	$48M	0.0%	$55.27	44
2025-Q1	Decreased	497,105	-8.0%	$24M	0.0%	$48.36	0
2024-Q4	Decreased	540,315	-14.1%	$20.9M	0.0%	$38.60	0
2024-Q3	Increased	628,623	+82.0%	$28.3M	0.0%	$45.00	44
2024-Q2	First report	345,293	-	$12M	0.0%	$34.65	0

PTGX9 quarters

PTGX
9 quarters